Type 1 diabetes (T1D) is an autoimmune disease, whereas type 2 diabetes (T2D) results from insulin resistance and beta cell dysfunction. Previously, the onset of these two separate diseases was easily distinguished, with children being most at risk for T1D and T2D occurring in overweight adults. However, the dramatic rise in obesity, coupled with the notable increase in T1D, has created a large overlap in these previously discrete patient populations. Delayed diagnosis of T1D can result in severe illness or death, and rapid diagnosis of T1D is critical for the efficacy of emerging therapies. However, attempts to apply next-generation platforms have been unsuccessful for detecting diabetes biomarkers. Here we describe the development of a plasmonic gold chip for near-infrared fluorescence-enhanced (NIR-FE) detection of islet cell-targeting autoantibodies. We demonstrate that this platform has high sensitivity and specificity for the diagnosis of T1D and can be used to discover previously unknown biomarkers of T1D.
t e c h n i c a l r e p o r t s Type 1 diabetes (T1D) is an autoimmune disease, whereas type 2 diabetes (T2D) results from insulin resistance and beta cell dysfunction. Previously, the onset of these two separate diseases was easily distinguished, with children being most at risk for T1D and T2D occurring in overweight adults. However, the dramatic rise in obesity, coupled with the notable increase in T1D, has created a large overlap in these previously discrete patient populations. Delayed diagnosis of T1D can result in severe illness or death, and rapid diagnosis of T1D is critical for the efficacy of emerging therapies. However, attempts to apply next-generation platforms have been unsuccessful for detecting diabetes biomarkers. Here we describe the development of a plasmonic gold chip for near-infrared fluorescence-enhanced (NIR-FE) detection of islet cell-targeting autoantibodies. We demonstrate that this platform has high sensitivity and specificity for the diagnosis of T1D and can be used to discover previously unknown biomarkers of T1D.
The World Health Organization projects that the global prevalence of diabetes will increase from 217 million cases in 2005 to 366 million by 2030 (ref. 1) . Diabetes remains a widespread disease in adults and is now the second most common chronic disease in children. For unclear reasons, the rate of T1D, or autoimmune diabetes, in children is rising by 3% annually [2] [3] [4] , with a projected 70% increase in prevalence between 2004 and 2020 (ref. 5) . Although T1D was once considered a pediatric disease, approximately one-fourth of affected individuals are now diagnosed during adulthood 6 . Concurrently, the rate of T2D, also called metabolic diabetes, has escalated exponentially in children since the early 1990s, related in part to the global obesity epidemic 1, 4, 7, 8 . As recently as 20 years ago, the probability of a young child developing T2D, or an overweight adult developing T1D, was low enough that diagnostic and treatment decisions were initiated on the basis of epidemiologic assumptions. However, the simultaneous rise in incidence of T1D and T2D 9, 10 has resulted in considerable overlap in the patient populations and a paradigm shift for these previously easily distinguishable diseases. A fundamental problem in current diabetes care is that diagnostic tests are slow and costly, delaying definitive diagnosis and making this key test inaccessible to regions of the globe with limited resources.
In addition to the fact that present platforms fail to meet current diagnostic needs, arising T1D therapies are critically dependent on faster diagnostics than these existing platforms can provide. Highly encouraging preliminary studies indicate that immune modulation and antigen-specific therapies fundamentally alter the natural history of T1D 11, 12 . These breakthrough therapies have the potential to protect pancreatic beta cell function as they move toward broad implementation in the patient population. However, early results from these studies indicate that therapeutic interventions are most effective when administered temporally close to the time of diagnosis, with delays as short as days to weeks potentially limiting efficacy 12, 13 . The current platforms for diagnosing diabetes are unable to meet this important emerging requirement and could prevent patients with T1D from receiving the maximum benefit from their therapy. In spite of the clear medical need, developing next-generation diagnostic tests has been unexpectedly challenging. Over the past two decades, many groups have demonstrated that the usual platforms, including lateral flow assays and ELISA, underperform when applied to T1D diagnostics, failing to meet the necessary sensitivity and specificity demands of this clinical situation 14, 15 .
The detection of autoantibodies against one or more pancreatic islet antigens (insulin, glutamic acid decarboxylase (GAD65) and/or tyrosine phosphatase islet antigen 2 (IA2 or ICA512)) in a patient with hyperglycemia is diagnostic of T1D and distinguishes the disease from T2D 16 . Screening for autoimmunity to islet cells in T1D sera was first described four decades ago using an indirect immunofluorescence assay on frozen sections of human pancreata 17 . Methodology has progressed with the identification of the three primary islet antigens 16 , and numerous international workshops have been conducted with a focus on improving T1D autoantibody measurements 18, 19 .
Autoantibodies against insulin are generally the first to appear in individuals with T1D and are classically the most difficult to detect 20 . Although it is not fully understood why detection of insulin-specific autoantibodies has been recalcitrant to standard approaches, the challenge has been attributed to the loss of critical tertiary structure in epitope binding sites when insulin is immobilized in solid-phase platforms 21 . Improved relative sensitivity has been achieved using radioimmunoassay (RIA) with target antigens in fluid phase 14 . However, the Diabetes Antibody Standardization Program demonstrated that RIA had poor overall performance and low sensitivity for detection of insulin-specific autoantibodies 20, 22 . This method remains the de facto standard for detection of autoantibody biomarkers of T1D, and there is currently no validated nonradioactive assay available 21 . Importantly, this method is time and labor intensive and is unable to provide results before a physician needs to initiate therapy, thus limiting the therapeutic options available to the patient.
Using recent advances in plasmonic gold substrate for NIR-FE detection 23, 24 , we developed a platform that overcomes the major challenges to rapid, sensitive and specific diagnosis of diabetes. This approach allows successful detection of T1D autoantibodies in ultralow volumes of human serum, such as that obtained from a fingerprick sample, with results available after a short processing time. We found that our platform has sensitivity and specificity equal to those of RIA. In addition, this new assay permits multiplexing of the islet antigens, provides autoantibody signal quantification, detects several isotypes of autoantibodies via multicolor fluorescence labeling on a single chip, is inexpensive and, notably, provides a point-ofcare platform.
RESULTS

Gold plasmonic chip enables detection of islet-targeting autoantibodies
To address the medical need for a rapid, sensitive and specific diagnostic test for diabetes, we first examined several platforms frequently used in other similar clinical situations, including lateral flow assays and ELISA. Consistent with what has been reported by others 14, 21, 25 , we were unable to achieve the needed sensitivity and specificity requirements using these standard platforms to detect islet antigen-specific autoantibodies (Supplementary Figs. 1 and 2 and Supplementary Table 1) .
We next applied nanotechnology to overcome the major obstacles of low signal intensity and poor sensitivity that we found using other approaches. We generated multiplexed islet antigen microarrays using nanostructured gold islands on a glass surface (Fig. 1a) . The gold islands ensure the generation of abundant nanogaps (~10-nm range) that support electric field enhancement and surface plasmonic resonance to improve NIR-FE detection by ~100-fold 23 (Fig. 1a) . In addition, we applied a biocompatible branched polyethylene glycol (PEG) layer over the gold islands to help preserve the native conformation of the islet antigens 26 (Fig. 1b) . To form a sandwich assay on this platform for islet-specific autoantibody quantification, we immobilized target islet antigen on the plasmonic chip, probed it with human serum (to capture specific autoantibodies against the target antigen) and then detected it with IRDye800-labeled anti-human IgG antibody. The abundance of specific autoantibody in the serum was reflected by the measured intensity of IRDye800 fluorescence (Fig. 1c) . A calibration curve for insulin-, GAD65-or IA2-specific autoantibodies was first obtained on a plasmonic chip using commercial reference samples containing known concentrations of the autoantibody. We observed a sensitivity increase of two to three orders of magnitude on the gold substrate compared with on glass. Notably, we obtained calibration titration curves exhibiting <10% coefficient variation with different batches of plasmonic chips in independent experiments even at low concentrations of autoantibodies, down to 0.1 U/ml (Fig. 1c) , demonstrating the high reproducibility and consistency of the plasmonic gold substrates. In contrast to the plasmonic gold substrates, vacuum-evaporated smooth gold films produced a fluorescence quenching, instead of enhancing, effect, resulting in lower sensitivity than traditional glass substrate (Fig. 1c) . Other microarray substrates, such as glass, nitrocellulose or smooth gold, had much lower sensitivity and specificity than the plasmonic gold surface ( Supplementary Figs. 2 and 3) . Notably, the plasmonic gold platform had better sensitivity than RIA for detecting insulin-specific autoantibodies (Fig. 1d) .
Detection of islet antigen-specific autoantibodies in ultralow volumes
In addition to improved sensitivity, the use of this plasmonic chip for diabetes diagnostics has several other advantages over RIA (Supplementary Table 2 ), including the ability to use ultralow sample volumes. RIA testing requires several milliliters of blood, making it necessary for patients to go to a phlebotomy laboratory. However, the most rapid and versatile way to confirm a diagnosis is at the point of care, such as a primary care physician's office. When the required volume of blood is ultralow, a sample may be obtained from a finger prick rather than requiring a phlebotomy laboratory. This capability would fundamentally alter the current diagnostic approach.
We constructed a plasmonic chip with a six-plexed antigen array for simultaneous multiple islet antigen-specific autoantibody detection with low sample volumes (Fig. 2a) . The islet antigens were each robotically printed in triplicate spots onto the branched PEG-coated gold film, resulting in a microarray with feature diameters of ~400 µm. As a technical positive control, we printed human IgG for recognition by the secondary detection antibody that we used. As a biological positive control, we printed tetanus toxoid, as immunization to tetanus is part of standard health care practice in the United States. Spots of PBS were used as negative controls.
To validate our platform using ultralow sample volumes, we tested volunteer patients with new-onset diabetes who were simultaneously undergoing standard RIA testing for islet antigen-specific autoantibodies. About 2 µl of human serum or blood was diluted 1:10 and used to probe the chips (Online Methods and Supplementary  Fig. 4 ). After processing (Online Methods), we analyzed the chips in a microarray scanner to detect and quantify the signals.
We detected positive signals on the IgG and tetanus spots and no signal on the PBS spots on every chip tested (Fig. 2a) . If a patient's serum contained autoantibodies against one or more islet antigens, we detected a positive signal specifically on the respective antigen spots (Fig. 2b) . With this technique, we also were able to detect T1D autoantibodies in ultralow volumes of whole-blood samples from humans (Fig. 2c) . The outcome of autoantibody detection in whole-blood samples was consistent with that in processed serum samples from the same patient (Fig. 2c) . The extremely small volume of blood required for our assay indicates that it will be feasible to use finger-prick sampling rather than venous blood draws (Fig. 2d) .
Plasmonic chip and RIA have the same sensitivity and specificity We collected samples from individuals with new-onset diabetes and nondiabetic controls at Stanford University Medical Center (Supplementary Table 3) . We excluded subjects for whom informed consent was not granted or not possible, and those known to have conditions such as active bleeding, severe anemia or other medical conditions whereby removal of an extra tube of blood would increase risk to the subject. In addition, we excluded any subject treated with insulin for more than 3 d, as exogenous insulin injected subcutaneously is thought to result in nonpathologic antibody production against this protein 27 . We collected samples from 39 patients with new-onset diabetes (26 were later diagnosed with T1D and 13 with T2D) and 5 nondiabetic controls.
To establish positive signal intensity cutoffs on the plasmonic chip, we tested spiked serum control samples containing autoantibodies at the cutoff concentration to determine their mean fluorescence intensity (MFI) equivalence on our platform (Fig. 1c) . To facilitate direct comparison of the described assay with the currently used standard, we tested an aliquot of the same blood samples used on the plasmonic gold chip using RIA in a commercial laboratory for every diabetic subject. The results of both assays were compared to the ultimate clinical diagnosis determined by disease progression and insulin requirement npg 6 months after the initial presentation (Online Methods). One subject with T1D had GAD65-specific autoantibody testing performed on a different RIA platform, and one subject with T2D had insulin-specific and GAD65-specific autoantibody testing performed on a different RIA platform; these values were not included for statistical analysis, and omitting these values did not improve the results. As expected, all of the nondiabetic controls tested negative for all three autoantibodies on the plasmonic gold chip platform ( Fig. 3 and Supplementary  Fig. 5 ). We tested samples from all the patients with diabetes for each autoantibody three different times, on different days, using different plasmonic chips, with excellent reproducibility ( Supplementary  Fig. 6 ). The mean titers for each autoantibody for every patient are plotted on the same graph in Figure 3 and individual autoantibody graphs in Supplementary Figure 5 . We found that the plasmonic gold chip and RIA both have a sensitivity of 100% and specificity of 85% in the patients tested ( Table 1) . We also evaluated the same serum samples tested on the plasmonic gold chip using microarrays formed on glass and nitrocellulose. We found that the NIR fluorescence signalto-noise ratios for the detection of islet antigen-specific autoantibodies were far superior on the plasmonic platform ( Supplementary  Fig. 2 and Supplementary Table 1 ).
Multiplexed detection of potentially new and early biomarkers
Although modern RIAs favor IgG detection in their protein A immunoprecipitation step, they do not distinguish among immunoglobulin isotypes 28, 29 . IgM antibodies are produced early in an immune response and are later replaced by isotype switching to IgG antibodies 30 . Taking advantage of our ability to enhance the fluorescence of multiple NIR dyes (e.g., Cy3, Cy5 and IRDye800 by ~3-, 50-and 100-fold, respectively (Supplementary Fig. 3) ) with non-overlapping emission spectra (Fig. 4a) , we achieved simultaneous detection of three subclasses of human autoantibodies (IgG, IgM and IgA) against each islet antigen (Fig. 4b) . This was done by using Cy3-labeled antihuman IgG secondary antibody, Cy5-labeled anti-human IgM secondary antibody and IRDye800-labeled anti-human IgA secondary antibody to probe the microarray spots of captured human IgG, IgM and IgA autoantibodies from a patient's serum. Of note, we chose the dye with the lowest NIR fluorescent enhancement for reporting the antibody subtype in the highest abundance in human serum. This was the first time multicolor microarrays were developed on a plasmonic substrate. Using this multicolor detection scheme, we identified a patient with new-onset diabetes who tested positive for IgM autoantibodies against insulin and GAD65 and positive for IgG autoantibodies against GAD65 and IA2 (Fig. 4c) . Although further research is needed to elucidate whether testing for IgM (or IgA) autoantibodies is clinically useful, this discovery exemplifies that the platform can be used as a new research tool that, unlike currently used panels, enables the testing of an enriched set of potential biomarkers.
DISCUSSION
For over two decades, it has been recognized that a rapid and globally accessible high-sensitivity diagnostic test for diabetes would substantially advance the field by allowing prompt diagnosis of patients that require T1D therapy and distinguishing the disease from T2D. In more recent years, this need has increased as it appears that expeditious intervention with next-generation T1D therapies affects the efficacy of these emerging treatments. In spite of this tremendous need, developing the technology has proved considerably more challenging than many other disease diagnostic platforms. T1D is defined by the detection of one or more islet antigen-specific autoantibodies. However, these biomarkers are difficult to identify and quantify with sufficient signal in human blood. When present, these antibodies are found at concentrations in the picomolar to femtomolar range, and it is challenging to differentiate their signals from other antibodies and blood components. We, and others, have demonstrated that traditional protein assays that use optical reporters, including ELISA and protein microarrays on nitrocellulose or glass substrates, fail to reliably detect diabetes autoantibodies. The low signal and high background noise when these assays are used to measure islet cell-targeting autoantibodies is a likely cause of these failures (Supplementary Fig. 2 ). This is further confounded by the inherent challenge of maintaining the native structure of the insulin epitopeautoantibody binding sites when immobilizing this important antigen on a solid surface 21 (Supplementary Fig. 7) . The unique surface chemistry of the plasmonic gold chip platform permits immobilization of islet antigens while preserving antibody binding. In addition, this surface chemistry maximizes analyte capture while resisting nonspecific binding, resulting in low background, and has a diagnostic sensitivity equivalent to that of RIA. Furthermore, the plasmonic gold chips have a batch-to-batch coefficient variation <10% at low analyte concentrations (down to 0.1 U/ml) (Fig. 1c,d and Supplementary  Fig. 6 ). NIR fluorescence enhancement on plasmonic gold films emanates from local electric field enhancement by the abundant nanoscale gaps between gold nanoislands and enhanced radiative decay rates or fluorescence quantum yield due to resonance emission dipole Figure 3 Scatter plot for diabetes autoantibodies. Analysis of our subject pool of 26 children with new-onset T1D, 13 children with new-onset T2D and 5 nondiabetic children demonstrates a specific (i.e., non-normal) distribution of MFI values for the patients with T1D. Each point represents an individual patient. The titer for each of the three autoantibodies for the individual patient is plotted on the three-dimensional axes. Points that fall within the blue box are negative for T1D by plasmonic gold platform testing. Ab, antibody. T1D specificity 85% 85%
Number of patients with:
Zero antibodies positive 11 11
One antibody positive 7 5 Two antibodies positive 7 9
Three antibodies positive 14 14 a Positive cutoff equivalence: insulin = 0.4 KU/ml, GAD65 = 5 U/ml and IA2 = 15 U/ml. Patients with one or more positive autoantibody were considered positive for T1D by that platform. npg coupling to plasmonic modes 31 . The NIR fluorescence enhancement of positive signals, combined with low, nonspecific background signals, are responsible for the broader dynamic range and lower limit of detection versus conventional substrates, leading to an improved sensitivity in T1D diagnosis (Fig. 1c,d and Supplementary Table 1) .
To our knowledge, this is the first time that protein microarrays on plasmonic gold chips have been used for human disease diagnosis. Furthermore, the ability to perform isotype-specific analysis enabled our identification of IgM and IgA autoantibodies. We are not aware of any previous report of multiplexed detection of these isotypes in a single assay platform for a patient with diabetes, demonstrating how this platform can be used as a new research tool to test for putative previously unknown biomarkers. Identifying biomarkers that can detect acute islet cell injury earlier than those currently used would greatly advance the field by facilitating an array of basic and clinical research opportunities.
Although RIA is the current standard for detecting T1D autoantibodies, this method is cumbersome and not readily available in some clinical settings. In addition to time intensity, other disadvantages of RIA include radioisotope requirement, cost, the inability to multiplex autoantibody detection and the relatively large amounts of serum required, necessitating venipuncture. Though ELISA is the standard for protein quantification and is widely used for research and clinical purposes, it is inadequate for autoantibody detection in T1D because of high background signals caused by nonspecific binding of human antibodies and changes in tertiary protein structure. The plasmonic gold platform allows simultaneous detection and quantification of autoantibodies to islet antigens and their isotypes. It requires only a 2-µl sample of whole blood without further processing to obtain serum. This can be acquired from a simple finger prick, which opens the possibility of point-of-care T1D diagnosis.
In addition to addressing the current clinical need for improved diabetes diagnostics, we believe that this technology will enable a broad range of advances in basic and clinical research that were not previously feasible. For example, serial monitoring of autoantibodies in patients undergoing new interventions might predict efficacy, as therapies that protect against continued islet cell destruction may correlate with a decline in autoantibody titer. Furthermore, following antibody levels at high resolution in patients considered high risk would yield great insight into the natural history of the development of diabetes. Ultimately, we believe this technology could be deployed to facilitate screening for islet antigen-specific autoantibodies, identifying those who would otherwise be at risk for progression to diabetic ketoacidosis and testing of preventative interventions prior to the onset of clinical symptoms.
METHODS
Methods and any associated references are available in the online version of the paper. 
